Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

NCT06298058 is registered in ClinicalTrials.gov with Shanghai Institute Of Biological Products as lead sponsor.

NCT NCT06298058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06298058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Lead sponsor
Shanghai Institute Of Biological Products
Phase
Phase 1
Overall status
Recruiting
Start date
May 9, 2024
Completion date
June 30, 2026
Enrollment
144 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor